Skip to content

Injecting users may need to start treatment earlier than other HIV+ people, US study reports

Nevirapine safe and effective in patients with a CD4 cell count below 200

US approval for once daily abacavir/3TC and tenofovir/FTC pills

Atazanavir: final phase III results published

Could monotherapy with Kaletra become an option for HIV treatment?

Initiating HAART with any one of four 3 x 5 drug choices leads to longest survival in San Francisco

Tenofovir has viral potency, a good lipid and safety profile, and should be available for first line HAART says study

Starting HAART soon after HIV infection leads to greater reduction in viral reservoir

EuroSIDA: patients with higher baseline CD4 have higher risk of immunologic failure on HAART